Jenburkt [JENBURPH] vs Gujarat Themis [GUJTHEM] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Jenburkt Pharmaceuticals Ltd. wins in 12 metrics, Gujarat Themis Biosyn Ltd. wins in 8 metrics, with 0 ties. Jenburkt Pharmaceuticals Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Jenburkt Pharmaceuticals Ltd. | Gujarat Themis Biosyn Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 14.42 | 73.73 | Jenburkt Pharmaceuticals Ltd. |
| Price-to-Book Ratio | 2.56 | 13.36 | Jenburkt Pharmaceuticals Ltd. |
| Debt-to-Equity Ratio | 0.93 | 27.04 | Jenburkt Pharmaceuticals Ltd. |
| PEG Ratio | -0.38 | -17.55 | Jenburkt Pharmaceuticals Ltd. |
| EV/EBITDA | 11.57 | 52.76 | Jenburkt Pharmaceuticals Ltd. |
| Profit Margin (TTM) | 19.63% | 29.99% | Gujarat Themis Biosyn Ltd. |
| Operating Margin (TTM) | 15.33% | 40.16% | Gujarat Themis Biosyn Ltd. |
| EBITDA Margin (TTM) | 15.33% | 40.16% | Gujarat Themis Biosyn Ltd. |
| Return on Equity | 18.66% | 19.64% | Gujarat Themis Biosyn Ltd. |
| Return on Assets (TTM) | 16.34% | 16.19% | Jenburkt Pharmaceuticals Ltd. |
| Free Cash Flow (TTM) | $81.92M | $-251.22M | Jenburkt Pharmaceuticals Ltd. |
| Dividend Yield | 2.48% | 0.17% | Jenburkt Pharmaceuticals Ltd. |
| 1-Year Return | -10.00% | 15.75% | Gujarat Themis Biosyn Ltd. |
| Price-to-Sales Ratio (TTM) | 2.83 | 22.23 | Jenburkt Pharmaceuticals Ltd. |
| Enterprise Value | $4.59B | $36.09B | Gujarat Themis Biosyn Ltd. |
| EV/Revenue Ratio | 2.78 | 22.65 | Jenburkt Pharmaceuticals Ltd. |
| Gross Profit Margin (TTM) | 79.57% | 83.29% | Gujarat Themis Biosyn Ltd. |
| Revenue per Share (TTM) | $374 | $15 | Jenburkt Pharmaceuticals Ltd. |
| Earnings per Share (Diluted) | $73.50 | $4.40 | Jenburkt Pharmaceuticals Ltd. |
| Beta (Stock Volatility) | 0.33 | -0.17 | Gujarat Themis Biosyn Ltd. |
Jenburkt Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Jenburkt Pharmaceuticals Ltd. | -1.09% | 1.28% | -2.09% | 15.56% | 6.36% | 6.69% |
| Gujarat Themis Biosyn Ltd. | -0.57% | -4.89% | 4.00% | 38.98% | -1.40% | -12.59% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Jenburkt Pharmaceuticals Ltd. | -10.00% | 65.07% | 145.34% | 194.80% | 1,213.55% | 5,074.07% |
| Gujarat Themis Biosyn Ltd. | 15.75% | 76.92% | 76.92% | 76.92% | 76.92% | 76.92% |
Performance & Financial Health Analysis: Jenburkt Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.
| Metric | JENBURPH | GUJTHEM |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.68B | ₹35.41B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,043 | 79,452 |
| 90 Day Avg. Volume | 1,047 | 106,446 |
| Last Close | ₹1,174.55 | ₹385.10 |
| 52 Week Range | ₹944.00 - ₹1,410.00 | ₹225.05 - ₹479.00 |
| % from 52W High | -16.70% | -19.60% |
| All-Time High | ₹1,410.00 (Jul 08, 2025) | ₹479.00 (Oct 27, 2025) |
| % from All-Time High | -16.70% | -19.60% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.17% | 0.10% |
| Quarterly Earnings Growth | -0.09% | -0.04% |
| Financial Health | ||
| Profit Margin (TTM) | 0.20% | 0.30% |
| Operating Margin (TTM) | 0.15% | 0.40% |
| Return on Equity (TTM) | 0.19% | 0.20% |
| Debt to Equity (MRQ) | 0.93 | 27.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹414.40 | ₹24.29 |
| Cash per Share (MRQ) | ₹21.86 | ₹0.92 |
| Operating Cash Flow (TTM) | ₹252.79M | ₹970.68M |
| Levered Free Cash Flow (TTM) | ₹320.61M | ₹487.72M |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.48% | 0.17% |
| Last 12-Month Dividend | ₹33.30 | ₹0.67 |
Valuation & Enterprise Metrics Analysis: Jenburkt Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.
| Metric | JENBURPH (Apr 24, 2026) | GUJTHEM (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 14.42 | 73.73 |
| Forward P/E | 30.41 | N/A |
| PEG Ratio | -0.38 | -17.55 |
| Price to Sales (TTM) | 2.83 | 22.23 |
| Price to Book (MRQ) | 2.56 | 13.36 |
| Market Capitalization | ||
| Market Capitalization | ₹4.68B | ₹35.41B |
| Enterprise Value | ₹4.59B | ₹36.09B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.78 | 22.65 |
| Enterprise to EBITDA | 11.57 | 52.76 |
| Risk & Other Metrics | ||
| Beta | 0.33 | -0.17 |
| Book Value per Share (MRQ) | ₹414.40 | ₹24.29 |
Financial Statements Comparison: Jenburkt Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | JENBURPH (2025) | GUJTHEM (2025) |
|---|---|---|
| Revenue/Sales | 1.51B | 1.51B |
| Cost of Goods Sold | 308.14M | 318.78M |
| COGS % of Revenue | 20.4% | 21.1% |
| Gross Profit | 1.21B | 1.19B |
| Gross Margin | 79.6% | 78.9% |
| Research & Development | 4.34M | 34.37M |
| Operating Income (EBIT) | 376.79M | 642.49M |
| Operating Margin | 24.9% | 42.6% |
| EBITDA | 461.81M | 713.04M |
| EBITDA Margin | 30.5% | 47.3% |
| Pre-Tax Income | 439.33M | 655.38M |
| Pre-Tax Income % of Revenue | 29.0% | 43.5% |
| Income Tax | 118.72M | 167.66M |
| Income Tax % of Revenue | 7.8% | 11.1% |
| Net Income (Profit) | 320.61M | 487.72M |
| Profit Margin | 21.2% | 32.3% |
Balance Sheet & Liquidity Metrics
| Metric | JENBURPH (2025) | GUJTHEM (2025) |
|---|---|---|
| Cash & Equivalents | 73.65M | 116.94M |
| Total Current Assets | 565.32M | 519.73M |
| Total Current Assets % of Revenue | 37.3% | 34.5% |
| Total Current Liabilities | 188.19M | 205.60M |
| Total Current Liabilities % of Revenue | 12.4% | 13.6% |
| Long-Term Debt | 14.92M | 296.36M |
| Long-Term Debt % of Revenue | 1.0% | 19.7% |
| Total Shareholders Equity | 1.72B | 2.48B |
| Retained Earnings | 1.62B | 2.37B |
| Retained Earnings % of Revenue | 107.3% | 157.4% |
| Property, Plant & Equipment | 144.29M | 411.30M |
Cash Flow Statement Comparison
| Metric | JENBURPH (2025) | GUJTHEM (2025) |
|---|---|---|
| Operating Cash Flow | 252.79M | 970.68M |
| Operating Cash Flow % of Revenue | 16.7% | 64.4% |
| Capital Expenditures | -197.14M | -1.16B |
| Free Cash Flow | 81.92M | -251.22M |
| FCF Margin | 5.4% | -16.7% |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | JENBURPH | GUJTHEM |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 4.41M | 108.97M |
| Float Shares | 1.26M | 29.52M |
| % Held by Insiders | 63.59% | 71.98% |
| % Held by Institutions | 0.00% | 1.18% |
| % Held by Public | 36.41% | 26.84% |
Dividend Analysis & Yield Comparison: Jenburkt Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.
| Metric | JENBURPH | GUJTHEM |
|---|---|---|
| Last 12-Month Dividend | ₹33.30 | ₹0.67 |
| Last 12-Month Dividend Yield | 2.48% | 0.17% |
| 3-Year Avg Annual Dividend | ₹19.90 | ₹0.22 |
| 3-Year Avg Dividend Yield | 1.83% | 0.17% |
| 3-Year Total Dividends | ₹59.70 | ₹0.67 |
| Ex-Dividend Date | Jul 11, 2025 | Sep 04, 2025 |